

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395	A1	(11) International Publication Number: WO 98/30241 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US98/00573 (22) International Filing Date: 9 January 1998 (09.01.98) (30) Priority Data: 60/034,672 10 January 1997 (10.01.97) US 60/040,154 7 March 1997 (07.03.97) US (71) Applicant (for all designated States except US): BIOGEN, INC. [US/US]; 14 Cambridge Center, Cambridge, MA 02142 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): KALLED, Susan, L. [US/US]; 2E Brewer Street, Jamaica Plain, MA 02130 (US). THOMAS, David, W. [US/US]; 9 Upland Road, Wellesley, MA 02182 (US). (74) Agent: FLYNN, Kerry, A.; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS OF THERAPEUTIC ADMINISTRATION OF ANTI-CD40L COMPOUNDS (57) Abstract Immune-related disorders can be effectively treated by administering anti-CD40L compounds at intervals of three weeks or more.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METHODS OF THERAPEUTIC ADMINISTRATION
OF ANTI-CD40L COMPOUNDS**

5

Field of the Invention

The invention relates to regimens for therapeutically administering anti-CD40L compounds to patients.

10

Background of the Invention

One of the necessary reactions in the generation of antibodies is the interaction of CD40 on B cells with CD40 ligand (CD40L) on activated T cells, a step which is required for B cell growth and subsequent production of antibodies. (Note: "gp39" is used synonymously for CD40L in some reports.) As further described below, a number of anti-CD40L

15

compounds have been produced, and some have been tested in animals for efficacy in altering the course of antibody-associated diseases.

The protocols used in the reported experiments on effects of anti-CD40L compounds on animals with immune disorders have employed doses of the compounds administered to the animals at intervals of two weeks or less, with typical intervals between treatments being 1-7
20 days. (See, e.g., Mohan et al., J. Immunol. 154: 1470-1480, 1995; Early et al., J. Immunol. 157: 3159-3164, 1996; Stüber et al., J. Exp. Med. 183:693-698, 1996; Chen et al., J. Immunol. 155:2833-2840, 1995; Gerritse et al., Proc. Natl. Acad. Sci. 93:2499-2504, 1996; Green et al., T. Virol. 70:2569-2575, 1996; Durie et al., Science 261:1328-1330, 1993; Durie et al., J. Clin. Invest. 94:1333-1338, 1994; Larsen et al., Transplantation 61:4-9, 1996;
25 and Griggs et al., J. Exp. Med 183:801-810, 1996). There has been no available information that suggests that less frequent administration of anti-CD40L compounds would be efficacious in inhibiting the production of pathologic antibodies or improving the course of immune-related diseases.

Summary of the Invention

30

The inventors have demonstrated that administering an anti-CD40L compound at intervals of three weeks or more is effective in treatment of disorders with antibody-related

-2-

pathogenesis. The invention provides a method of treating a patient with an antibody-related disease, which includes administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and the second day. Similar amounts of an anti-CD40L compound may
5 subsequently be given to the patient, with at least about 3 weeks between successive doses. In one embodiment, the interval between doses is at least about 4 weeks.

In another aspect of the invention, a method is taught for treating a patient with an antibody-related disease, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient for a first therapeutic period at intervals of less than
10 about 3 weeks, then administering a therapeutically effective amount of an anti-CD40L compound to the patient for a second therapeutic period at intervals of at least about 3 weeks or at least about 4 weeks.

A further application for the above-described administration regimens is for treating a patient with a chronic immune system disorder, such as psoriasis, allergic conditions, arthritis
15 or multiple sclerosis.

In another embodiment, the methods of the invention are useful for treating a chronic autoimmune disease, such as systemic lupus erythematosus, myasthenia gravis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, or anti-phospholipid syndrome.

Yet another aspect of the invention provides a method of inhibiting rejection of
20 transplanted tissue within a patient; this method includes administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and the second day. The compound may be given subsequently at varying intervals, but in one embodiment, it is given subsequent to the second dose at intervals of at least about 3 weeks or at least about 4 weeks.
25 The transplanted tissue may be any organ or tissue which is suitable for transplantation. Particularly intended for inclusion are transplants of skin, kidney, liver, heart, bone marrow, or eye tissue. The graft may be an allograft or a xenograft.

The methods of the invention may also be useful in suppressing immune reaction after gene therapy.

-3-

In an alternative dosing regimen for inhibiting rejection of transplanted tissue within a patient, an anti-CD40L compound is administered to the patient for a first therapeutic period at intervals of less than about 3 weeks, then administering for a second therapeutic period at intervals of at least about 3 weeks.

5 The anti-CD40L compound may be any compound that binds to CD40L on the surface of CD40L-expressing cells, such as activated T cells. In one embodiment, the compound is an anti-CD40L antibody, preferably a monoclonal antibody. The monoclonal antibody may be 5c8 (ATCC Accession No. HB 10916).

10 The anti-CD40L compound may be formulated in a therapeutic composition which includes a therapeutically-effective amount of the anti-CD40L compound and a pharmaceutically acceptable carrier. The therapeutic composition may also include a second therapeutically effective compound.

Brief Description of the Drawings

15 Fig. 1 is a chart of the changes with time in several measured characteristics of blood and urine from control and treated (SWR X NZB) F₁ mice in Experiment II. The anti-CD40L mAb MR1, at 500 ug/animal i.p., was administered once when the mice were 4 months old, again at 7 months of age, again at 9 months, and then at monthly intervals. Each of the upper five rows of the chart, marked AR-BN, contains data from a single control animal, and each of
20 the lower six rows, marked CL-CR, contains data from a single treated animal. This study began when the animals were 4 months of age, in February 1996. The vertical double lines separate 4 groups of data, each data group providing the measurements for urine and blood samples collected on the date listed above the data. Proteinuria (PU) levels are indicated from trace to level 4. Level 1 correlates with urine albumin of 30 mg/dl albumin, level 2 with
25 100 mg/dl, level 3 with 300 mg/dl, and level 4 with over 2000 mg/dl. Levels of anti-MR1 antibodies (provided in column labeled "anti-MR1"), anti-ssDNA antibodies and anti-dsDNA antibodies are given in µg/ml blood. Where appropriate, values are given as mean and standard deviation of several samples, in the form mean(S.D.). A dash indicates that a sample was not collected, typically because the animal had died. ND refers to "not done."

-4-

Fig. 2 is a chart of proteinuria measurements of the Experiment II animals over time. The first column provides the animal numbers as in Fig. 1. The columns are headed with the dates of sample collection. NC means "not collected."

5 Fig. 3 is a chart of blood and urine characteristics with time in Experiment V control and untreated mice, which started treatment at 4.5 months of age. MR1 was administered to treated animals once at 500 ug/animal i.p. when the mice were 4.5 months old, and then as monthly injections of 500 ug, i.p. Each of the upper seven rows of the chart, marked AR-BLR, contains data from a single control animal, and each of the lower seven rows, marked
10 CR -CLR, contains data from a single treated animal. This study began when the animals were 4.5 months of age, in May 1996. Other descriptions of the figure are the same as those of Fig. 1.

Fig. 4 is a chart of proteinuria measurements of the Experiment V animals over time. Animal
15 numbers are as described for Fig. 3. Other descriptions of the figure are the same as those of Fig. 2.

Fig. 5 is a chart of chart of blood and urine characteristics with time in Experiment VII control and untreated mice, which started treatment at 5.5 months of age. MR1 was administered to
20 treated animals once weekly at 500 ug/animal i.p. for six weeks, followed by monthly injections of 500 ug, i.p. Each of the upper three rows of the chart, marked AN-BL, contains data from a single control animal (as noted in Fig. 6, some control animals had died before the data for Fig. 5 was collected), and each of the lower seven rows, marked CR-DN , contains data from a single treated animal. This study began when the animals were 5.5 months of
25 age, in June 1996. Other descriptions of the figure are the same as those of Fig. 1.

Fig. 6 is a chart of proteinuria measurements of the Experiment VII animals over time. Each of the upper seven rows of the chart, marked AR-BN, contains data from a single control animal, and each of the lower seven rows, marked CR-DN , contains data from a single
30 treated animal. Other descriptions of the figure are the same as those of Fig. 2.

-5-

Fig. 7 is a chart of blood and urine characteristics with time in Experiment X control and untreated mice, which started treatment at 5.5 months of age. MR1 was administered to treated animals once weekly at 500 ug/animal i.p. for four weeks, followed by monthly injections of 200 ug, i.p. Each of the upper eight rows of the chart, marked AR-BLR, contains data from a single control animal, and each of the lower eight rows, marked CR-DLR, contains data from a single treated animal. This study began when the animals were 5.5 months of age, in October 1996. Other descriptions of the figure are the same as those of Fig. 1.

Fig. 8 is a chart of proteinuria measurements of the Experiment X animals over time. The first column provides the animal numbers as in Fig. 7. Other descriptions of the figure are the same as those of Fig. 2.

Fig. 9 is a chart of blood and urine characteristics with time in Experiment VI control and untreated mice, which started treatment at 7 months of age. MR1 was administered to 4 treated animals once weekly at 500 ug/animal i.p. for six weeks, followed by monthly injections of 500 ug, i.p. Each of the lower four rows, marked DN-EN, contains data from a single treated animal. At the time of first data collection for this chart, all control animals had died, as noted Fig. 10. This study began when the animals were 7 months of age, in June 1996. Other descriptions of the figure are the same as those of Fig. 1.

Fig. 10 is a chart of proteinuria measurements of the Experiment VI animals over time. Each of the upper four rows of the chart, marked AR-CN, contains data from a single control animal, and each of the lower four rows, marked DN-EN, contains data from a single treated animal. Other descriptions of the figure are the same as those of Fig. 2.

Detailed Description of the Invention

The method of the invention involves treating, preventing, reversing or stabilizing a patient with an antibody-related disease, by treating the patient with an anti-CD40L

-6-

compound at intervals of more than two weeks. The compound blocks the interaction of CD40L on T cells with CD40 on B cells, which is thought to inhibit the production of pathologic antibodies responsible for many of the pathologic effects of various autoimmune diseases and chronic immune disorders.

5

Compounds

Therapeutic compounds useful for the methods of the invention include any compound that blocks the interaction of CD40 on B cells with CD40L expressed on the surface of activated T cells. Anti-CD40L compounds specifically contemplated include polyclonal
10 antibodies and monoclonal antibodies (mAbs), as well as antibody derivatives such as chimeric molecules, humanized molecules, molecules with reduced effector functions, bispecific molecules, and conjugates of antibodies. In a preferred embodiment, the antibody is 5c8, as described in U.S. Patent 5,474,771, the specification of which is hereby incorporated by reference. Other known antibodies against 5c8 antigen include antibodies ImxM90,
15 ImxM91 and ImxM92 (obtained from Immunex), an anti-CD40L mAb commercially available from Ancell (clone 24-31, catalog # 353-020, Bayport, MN), and an anti-CD40L mAb commercially available from Genzyme (Cambridge, MA, catalog # 80-3703-01). Also commercially available is an anti-CD40L mAb from PharMingen (San Diego, catalog #33580D). Numerous additional anti-CD40L antibodies have been produced and
20 characterized (see, e.g., WO 96/23071 of Bristol-Myers Squibb, the specification of which is hereby incorporated by reference).

The invention also includes anti-CD40L molecules of other types, such as complete Fab fragments, $F(ab')_2$ compounds, V_H regions, F_V regions, single chain antibodies (see, e.g., WO 96/23071), polypeptides, fusion constructs of polypeptides, fusions of CD40 (such as
25 CD40Ig, as in Hollenbaugh et al., J. Immunol. Meth. 188:1-7, 1995, which is hereby incorporated by reference), and small molecule compounds such as small semi-peptidic compounds or non-peptide compounds, all capable of blocking the CD40-CD40L interaction. Procedures for designing, screening and optimizing small molecules are provided in the patent application PCT/US96/10664, filed June 21, 1996, the specification of which is hereby
30 incorporated by reference.

-7-

Various forms of antibodies may also be produced using standard recombinant DNA techniques (Winter and Milstein, Nature 349: 293-99, 1991). For example, "chimeric" antibodies may be constructed, in which the antigen binding domain from an animal antibody is linked to a human constant domain (an antibody derived initially from a nonhuman mammal in which recombinant DNA technology has been used to replace all or part of the hinge and constant regions of the heavy chain and/or the constant region of the light chain, with corresponding regions from a human immunoglobulin light chain or heavy chain) (see, e.g., Cabilly et al., United States patent 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. 81: 6851-55, 1984). Chimeric antibodies reduce the immunogenic responses elicited by animal antibodies when used in human clinical treatments.

In addition, recombinant "humanized" antibodies may be synthesized. Humanized antibodies are antibodies initially derived from a nonhuman mammal in which recombinant DNA technology has been used to substitute some or all of the amino acids not required for antigen binding with amino acids from corresponding regions of a human immunoglobulin light or heavy chain (chimeras comprising mostly human IgG sequences into which the regions responsible for specific antigen-binding have been inserted)(see, e.g., PCT patent application WO 94/04679). Animals are immunized with the desired antigen, the corresponding antibodies are isolated and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived antigen binding regions are then cloned into the appropriate position of the human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (inter-species) sequences in human antibodies and are less likely to elicit immune responses in the treated subject.

Also useful in the methods and compositions of this invention are primate or primatized antibodies.

Antibody fragments and univalent antibodies may also be used in the methods and compositions of this invention. Univalent antibodies comprise a heavy chain/light chain dimer bound to the Fc (or stem) region of a second heavy chain. "Fab region" refers to those portions of the chains which are roughly equivalent, or analogous, to the sequences which comprise the Y branch portions of the heavy chain and to the light chain in its entirety, and

-8-

which collectively (in aggregates) have been shown to exhibit antibody activity. A Fab protein includes aggregates of one heavy and one light chain (commonly known as Fab'), as well as tetramers which correspond to the two branch segments of the antibody Y, (commonly known as F(ab)₂), whether any of the above are covalently or non-covalently aggregated, so long as the aggregation is capable of selectively reacting with a particular antigen or antigen family.

In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a humanized antibody may be increased by mutagenesis based on molecular modeling (Queen et al., Proc. Natl. Acad. Sci. 86:10029-33, 1989; PCT patent application WO 94/04679). It may be desirable to increase or to decrease the affinity of the antibodies for CD40L, depending on the targeted tissue type or the particular treatment schedule envisioned. This may be done utilizing phage display technology (see, e.g., Winter et al., Ann. Rev. Immunol. 12:433-455, 1994; and Schier et al., J. Mol. Biol. 255:28-43, 1996, which are hereby incorporated by reference). For example, it may be advantageous to treat a patient with constant levels of antibodies with reduced affinity for CD40L for semi-prophylactic treatments. Likewise, antibodies with increased affinity for CD40L may be advantageous for short-term treatments.

20 Subjects

The term "patient" is taken to mean any mammalian patient to which anti-CD40L compounds may be administered. Patients specifically intended for treatment with the method of the invention include humans, as well as nonhuman primates, sheep, horses, cattle, goats, pigs, dogs, cats, rabbits, guinea pigs, hamsters, gerbils, rats and mice, as well as the organs, tumors, and cells derived or originating from these hosts.

The subjects for which the methods of the invention are intended have disease related to antibody production.

Routes of Administration

-9-

The compounds of the invention may be administered in any manner which is medically acceptable. This may include injections, by parenteral routes such as intravenous, intravascular, intraarterial, subcutaneous, intramuscular, intratumor, intraperitoneal, intraventricular, intraepidural, or others as well as oral, nasal, ophthalmic, rectal, or topical.

5 Sustained release administration is also specifically included in the invention, by such means as depot injections. Some forms of anti-CD40L compounds may be suitable for oral administration, and could be formulated as suspensions or pills.

Dosages and Frequency of Treatment

10 The amount of and frequency of dosing for any particular compound to be administered to a patient for a given immune complex disease is a judgment made by the patient's physician, based on a number of factors. The general dosage is established by preclinical and clinical trials, which involve extensive experiments to determine the beneficial and deleterious effects on the patient of different dosages of the compound. Even after such
15 recommendations are made, the physician will often vary these dosages for different patients based on a variety of considerations, such as a patient's age, medical status, weight, sex, and concurrent treatment with other pharmaceuticals. Determining the optimal dosage for each anti-CD40L compound used to treat lupus nephritis is a routine matter for those of skill in the pharmaceutical and medical arts.

20 Various regimens may be used for treatment of lupus or other immune complex diseases according to this invention. Generally, the frequency of dosing would be determined by the attending physician, and might include periods of greater dosing frequency, such as at daily or weekly intervals, alternating with periods of less frequent dosing, such as at monthly or longer intervals.

25 To exemplify dosing considerations for an anti-CD40L compound, the following examples of administration strategies are given for an anti-CD40L mAb. The dosing amounts could easily be adjusted for other types of anti-CD40L compounds. In general, single dosages of between about 0.05 and about 50 mg/kg patient body weight are contemplated, with dosages most frequently in the 1-20 mg/kg range. For acute treatment, an effective dose
30 of antibodies ranges from about 1 mg/kg body weight to about 20 mg/kg body weight,

-10-

administered daily for a period of about 1 to 5 days, preferably by bolus intravenous administration. The same dosage and dosing schedule may be used in the load phase of a load-maintenance regimen, with the maintenance phase involving intravenous or intramuscular administration of antibodies in a range of about 0.1 mg/kg body weight to about 20 mg/kg body weight, for a treatment period of anywhere from weekly to 3 month intervals. Chronic treatment may also be carried out by a maintenance regimen, in which antibodies are administered by intravenous or intramuscular route, in a range of about 0.1 mg/kg body weight to about 20 mg/kg body weight, with interdose intervals being anywhere between about 1 week and about 3 months. In addition, chronic treatment may be effected by an intermittent bolus intravenous regimen, in which between about 1.0 mg/kg body weight and about 100 mg/kg body weight of antibodies are administered, with the interval between successive treatments being from 1 to 6 months. For all except the intermittent bolus regimen, administration may also be by oral, pulmonary, nasal or subcutaneous routes.

Generally, therapy is commenced with low doses of antibodies. For example, an initial dose of antibodies is administered to the patient by, for example, injection or infusion. That initial dose should contain between about 1.0 mg and 30 mg of antibodies per day for a 70 kg patient. For repeated administrations over several days, dosages may be administered on successive days, every two to six days, once a week, every two to four weeks or once a month, until a desired suppression of disease symptoms is observed. However, other dosage regimens are also useful. When the symptoms have been alleviated to the desired level, treatment may cease. Patients may, however, require intermittent treatment on a long term basis upon recurrence of disease symptoms.

According to an alternate embodiment of this invention for treatment of lupus or other antibody-related diseases, the effectiveness of the antibodies may be increased by administration serially or in combination with conventional anti-lupus therapeutic agents or drugs such as, for example, salicylates, corticosteroids or immunosuppressants. Alternatively, the antibodies may be conjugated to a conventional agent. This advantageously permits the administration of the conventional agent in an amount less than the conventional dosage, for example, less than about 50% of the conventional dosage, when the agent is administered as

-11-

monotherapy. Accordingly, the occurrence of many side effects associated with that agent might be avoided.

Combination therapies according to this invention for treatment of lupus include the use of anti-CD40L antibodies together with agents targeted at B cells, such as anti-CD19, anti-
5 CD28 or anti-CD20 antibody (unconjugated or radiolabeled), IL-14 antagonists, LJP394 (LaJolla Pharmaceuticals receptor blocker), IR-1116 (Takeda small molecule) and anti-Ig idiotype monoclonal antibodies. Alternatively, the combinations may include T cell/B cell targeted agents, such as CTLA4Ig, IL-2 antagonists, IL-4 antagonists, IL-6 antagonists, receptor antagonists, anti-B7 monoclonal antibodies, TNF, LFA1/ICAM antagonists,
10 VLA4/VCAM antagonists, brequinar and IL-2 toxin conjugates (e.g., DAB), prednisone, cyclophosphamide, and other immunosuppressants. Combinations may also include T cell targeted agents, such as CD4 antagonists, CD2 antagonists and IL-12.

Combination therapies for treatment of a patient with a non-lupus immune complex disease might involve administration of an anti-CD40L compound as well as an agent which
15 would typically be administered for the particular immune complex disease in question.

Once improvement of the patient's condition has occurred, a maintenance dose of anti-CD40L antibodies, alone or in combination with a conventional anti-lupus agent is administered, if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved
20 condition is retained. When the symptoms have been alleviated to the desired level, treatment might cease. In other instances, as determined by a patient's physician, occasional treatment might be administered, for example at intervals of four weeks or more. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

25

Formulation

An anti-CD40L compound used in the methods of the invention is administered in a pharmaceutically-effective amount, which is an amount which produces a medically beneficial effect on a patient with an antibody-related disease, an immune-associated disorder, or a
30 patient with a transplant or a transgene for which suppression of rejection is desirable..

-12-

Medically beneficial effects would include preventing deterioration or causing improvement in the patient's medical condition. As an example, an organ that is often damaged by pathologic antibodies is the kidney in SLE patients. In these patients, treated with the methods of the invention, renal function and health may be monitored with one or more

5 laboratory tests which measure the concentrations of relevant substances in blood or urine, other urine characteristics, or the rate of clearance of various substances from the blood into the urine. The parameters measured by these tests, either individually or in combination, can be used by a physician to assess renal function or damage. Examples of such parameters include the blood concentration of urea, creatinine or protein; the urine concentration of

10 protein or of various blood cells such as erythrocytes or leucocytes; urine specific gravity; amount of urine; the clearance rates of inulin, creatinine, urea or p-aminohippuric acid; and the presence of hypertension or edema. Medically beneficial effects would also include the diminution of autoantibodies, such as anti-dsDNA antibodies in the serum of lupus patients.

An anti-CD40L compound of the invention is administered to a patient in a

15 pharmaceutically acceptable composition, which may include a pharmaceutically-acceptable carrier. Such a carrier is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the anti-CD40L compound or other active ingredients, so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredients of the composition. The composition may include other compatible substances;

20 compatible, as used herein, means that the components of the pharmaceutical composition are capable of being commingled with the anti-CD40L compound, and with each other, in a manner such that there is no interaction which would substantially reduce the therapeutic efficacy of the pharmaceutical. Nasal spray formulations comprise purified aqueous solutions of the active compound with preservative agents and isotonic agents. Such formulations are

25 preferably adjusted to a pH and isotonic state compatible with the nasal mucous membranes. Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, tablets, pills or lozenges, each containing a predetermined amount of the potentiating anti-CD40L compound as a powder or granules; as liposomes; or as a suspension in an aqueous liquor or non-aqueous liquid such as a syrup, an

30 elixir, an emulsion or a draught.

Use of Anti-CD40L Compounds Administered at Wide Intervals to Treat Lupus Nephritis in Nonhuman Subjects

We chose to demonstrate the efficacy of administering anti-CD40L compounds in an animal model of lupus nephritis. Systemic lupus erythematosus (SLE) is a life threatening autoimmune disease, characterized by the production of autoantibodies against various tissues, and often against DNA. SLE affects approximately 140,000 people in the United States and 105,000 in western Europe, predominantly women of childbearing age. In most patients, lupus-associated immunoglobulins and immune complexes are deposited in the renal glomeruli, causing a decline in renal function. If widely spaced doses of anti-CD40L compounds are efficacious in selectively suppressing antibody production, such a dosing regime would exert beneficial effects on nephritis. This could be evidenced in treated animals by slower progression of nephritis, reduced severity of nephritis, enhanced survival, or even by improvement of renal function in some animals.

We tested the effects of the hamster anti-muCD40L mAb MR1 on the course of nephritis in the female (SWR X NZB) F₁ mouse, in several studies as described below. Control animals were injected either with Syrian hamster polyclonal Ig or with Ha4/8, an Armenian hamster mAb directed against KLH. Proteinuria levels are indicated from trace to level 4. Level 1 correlates with urine albumin of 30 mg/dl albumin, level 2 with 100 mg/dl, level 3 with 300 mg/dl, and level 4 with over 2000 mg/dl. A level of 2 was considered to indicate moderate nephritis, with 2.5 and greater indicating severe nephritis.

If untreated, or if treated with the nonspecific hamster immunoglobulins administered to control animals, the mice normally die by 12 months of age. While the onset of proteinuria in untreated animals is variable, most have mild to moderate proteinuria by 3 months of age; the proteinuria tends to increase with age. By about 5 months of age, all control animals typically have detectable anti-dsDNA antibodies, and most have detectable anti-ssDNA antibodies; this contrasts with the complete lack of detectable levels of these antibodies in normal mice, such as the female SWR parents of the (SWR X NZB) F₁ mice.

Experiment II: Treatment begun at 4 months (Figs. 1 and 2)

-14-

MR1 treatment was initiated when the mice were 4 months of age. MR1 was administered to treated animals once at 500 ug/animal i.p. when the mice were 4 months old, once at 7 months of age, and once at 9 months followed by once-monthly injections. After 4 months of treatment, 4 of the 5 control animals had died, but four of the six treated animals were yet alive. Three of these four previously surviving treated mice died, one each at 12, 13 and 13.5 months. One still survives, and is now 15 months old, an extraordinary longevity for mice of this cross. Of great interest, the surviving animal (mouse II:DN on Figure 2) had moderate nephritis (2+ proteinuria) from ages 8 to 13 months, which has decreased to only trace levels of proteinuria for the last two months. This is the first demonstration of a functional reversal of nephritis in a mouse of this strain.

Experiment V: Treatment begun at 4.5 months (Figs. 3 and 4)

MR1 treatment was initiated when the mice were 4.5 months of age. MR1 was administered to treated animals once at 500 ug/animal i.p. when the mice were 4.5 months old, and then as monthly injections of 500 ug, i.p. After 4.5 months, 6 of the 7 control animals had died, but six of the seven treated animals survived. After 8 months of treatment, all controls were dead, but only three of the seven treated mice had died. As shown in Fig. 4, four of the seven MR1-treated animals had their nephritis reversed as shown by sustained lowered proteinuria levels. These four animals are still alive at age 12.5 months.

Experiment VII: Treatment begun at 5.5 months (Figs. 5 and 6)

MR1 treatment was initiated when the mice were 5.5 months of age. MR1 at 500 µg/animal i.p. was administered to treated animals once weekly for six weeks, followed by monthly injections. After 5 months of treatment, at age 10.5 months, 6 of the 7 control animals had died; all of the 7 treated animals are still alive at age 12 months. The following values were measured in the animals which still survived at 8.5 months, after 3.5 months of treatment:

	<u>anti-SS-DNA</u>	<u>anti-DS DNA</u>	<u>PU</u>
control	2.4	0	4

-15-

		8.8	6.3	4
		6.3	10.1	4
	Mean (Std. Dev.)	5.8 (2.6)	5.4 (4.1)	4 (0)
5	MR1	2.7	0	1
		2.0	0	1.5
		2.0	1.5	3
		0	0	2
		2.7	0	1
10		0	0	2
		3.5	0	1.5
	Mean (Std. Dev.)	1.8 (1.2)	0.2 (0.5)	1.7 ()

Experiment X: Less intensive treatment, begun at 5.5 months (Figs. 7 and 8)

15 MR1 treatment was initiated when the mice were 5.5 months of age. MR1 was administered to treated animals once weekly at 500 ug/animal i.p. for four weeks, followed by monthly injections of 200 µg, i.p. Of the 16 mice in the study (8 each in control and treated groups), now 8.5 months of age, only one mouse has died, a control animal at age 7.5 months. As shown in Fig. 8, seven of the eight control animals had proteinuria which steadily

20 increased to high levels, averaging +3.4 for the 7 surviving control mice. All but one of the eight MR1- treated mice have maintained low proteinuria, which currently averages +2 for the 8 treated mice. As shown in Fig. 7, six of the treated animals, but only one of the controls, have no detectable anti-dsDNA antibodies.

25 Experiment VI: Treatment begun at 7 months (Figs. 9 and 10)

MR1 treatment was initiated when the mice were seven months of age. MR1 was administered to 4 treated animals once weekly at 500 ug/animal i.p. for six weeks, followed by monthly injections of 500 ug, i.p. By age 10 months, all 4 control animals had died. While 2 of the treated mice died at age 11 months, and a third at 13 months, one of the four treated

30 animals remains alive currently at 14 months of age, after 7 months of treatment. The

-16-

surviving treated animal (number VI:ER) currently has level 1 proteinuria, and detectable anti-dsDNA and anti-ssDNA antibodies.

These experiments show that treatment of (SWR X NZB) F₁ mice with anti-CD40L mAb, administered for at least a period of time at intervals of over 3 weeks, markedly and
5 consistently prolongs survival as compared to control animals, and slows development of nephritis as indicated by proteinuria levels. In some animals, the treatment actually reverses nephritis, as shown by a reduction in proteinuria levels. Of 32 treated animals, 11 had urine protein levels which decreased with anti-CD40L mAb therapy; none of the control animals had similar reductions. Of 24 treated animals in which serum blood urea nitrogen (BUN) was
10 measured, 3 had decreases in BUN levels after treatment, which was not observed in any control animal. In addition, MR1 treatment often results in a reduced serum concentration of anti-DS and anti-SS DNA autoantibodies, which are normally produced in untreated animals of this type.

The disease-reducing or -preventing results of these experiments demonstrate that anti-
15 CD40L compounds may successfully be used to treat antibody-associated conditions when administered at intervals of 3 or more weeks. This is a surprising and unanticipated finding, which confers significant advantages over previously contemplated dosing regimens. Particularly for patients being treated for a chronic disease, reduced frequency of treatments results in lowered cost, inconvenience, and discomfort, particularly for injectable or
20 intravenous treatments. In addition, any side effects of treatment would be expected to be reduced with fewer and more widely spaced dosings.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one skilled in the art that certain changes and modifications may be practiced within the scope of
25 the invention, as limited only by the scope of the appended claims.

-17-

Claims

1. A method of treating a patient with an antibody-related disease, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and the second day.
5
2. The method of claim 1, further comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient on a third day, with an interval of at least about 3 weeks between the second day and the third day.
- 10 3. The method of claim 1, wherein the interval between the first day and the second day is at least about 4 weeks, at least about 6 weeks, or at least about 8 weeks.
4. A method of treating a patient with an antibody-related disease, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient for a first
15 therapeutic period at intervals of less than about 3 weeks, then administering a therapeutically effective amount of an anti-CD40L compound to the patient for a second therapeutic period at intervals of at least about 3 weeks.
5. The method of claim 4, wherein the anti-CD40L compound is administered for the second
20 therapeutic period at intervals of at least about 4 weeks.
6. A method of treating a patient with a chronic autoimmune disease, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and
25 the second day.
7. The method of claim 6, further comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient on a third day, with at least about 3 weeks between the second day and the third day.

-18-

8. The method of claim 6, wherein there is at least about 4 weeks between the first day and the second day.

9. A method of treating a patient with a chronic immune system disorder, comprising
5 administering a therapeutically effective amount of an anti-CD40L compound to the patient for a first therapeutic period at intervals of less than about 3 weeks, then administering a therapeutically effective amount of an anti-CD40L compound to the patient for a second therapeutic period at intervals of at least about 3 weeks.

10 10. The method of claim 9, wherein the anti-CD40L compound is administered for the second therapeutic period at intervals of at least about 4 weeks.

11. The method of claim 9, wherein the chronic immune disorder is systemic lupus erythematosus, an allergic disorder, myasthenia gravis, autoimmune hemolytic anemia,
15 idiopathic thrombocytopenic purpura, or anti-phospholipid syndrome.

12. The method of claim 9, wherein the chronic immune disorder is psoriasis, arthritis or multiple sclerosis.

20 13. The method of claim 9, wherein the anti-CD40L compound is an anti-CD40L antibody.

14. The method of claim 13, wherein the antibody is a monoclonal antibody.

15. The method of claim 14, wherein the monoclonal antibody is 5c8.

25

16. The method of claim 9, wherein the anti-CD40L compound is formulated in a therapeutic composition comprising a therapeutically-effective amount of the anti-CD40L compound and a pharmaceutically acceptable carrier.

-19-

17. The method of claim 16, wherein the therapeutic composition further comprises a second therapeutically effective compound.

18. A method of inhibiting rejection of transplanted tissue within a patient, comprising
5 administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and the second day.

19. The method of claim 18, further comprising administering a therapeutically effective
10 amount of an anti-CD40L compound to the patient on a third day, with at least about 3 weeks between the second day and the third day.

20. The method of claim 18, wherein there is at least about 4 weeks between the first day and the second day.

15

21. The method of claim 18, wherein the transplanted tissue is a kidney, liver, or heart.

22. The method of claim 18, wherein the transplanted tissue is an allograft or a xenograft.

20 23. A method of inhibiting rejection of transplanted tissue within a patient, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient for a first therapeutic period at intervals of less than about 3 weeks, then administering a therapeutically effective amount of an anti-CD40L compound to the patient for a second therapeutic period at intervals of at least about 3 weeks.

25

24. A method of inhibiting immune reaction to the gene product of a transgene within a patient, comprising administering a therapeutically effective amount of an anti-CD40L compound to the patient on a first day and again on a second day, with at least about 3 weeks between the first day and the second day.

1/10

	4-11-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	5-10-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml
11	PU	MR1 ug/ml							
AR	2.5	ND	4.6 (0.26)	0	3	ND	ND	1.7 (0.12)	0
AL	4	ND	1.2 (0.05)	0	4	ND	ND	6.5 (2.3)	5.7(0.98)
AN	4	ND	2.8 (0.08)	1.24 (0.06)	"	"	"	"	"
BR	4	ND	0	0	"	"	"	"	"
BN	3	ND	8.8 (0.04)	0.47 (0.05)	4+	ND	ND	> 25.5(1.6)	13.8(0.71)
CL	2	6.5 (0.3)	5.9 (0.36)	6.5 (0.84)	2	0	21.1 (2.2)	> 67.5(1.97)	> 39.14(1.82)
CLR	2	15.9 (2.1)	0	0	3	0.9 (0.1)	0	1.5(0.7)	0
DR	1.5	25.7 (2.5)	18.1 (0.7)	9.5 (0.9)	2	4.9 (1)	0	ND	1.4(0.1)
DN	1	36.1 (1.6)	0	0	2	1.8 (0.2)	0	1.5 (0.3)	0
CN	2	0	0.8 (0.04)	0	"	"	"	ND	ND
CR	3	0	1.4 (0.13)	0	"	"	"	ND	ND

	10-2-96	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml
4	ND	ND	6.2 (0.8)	3.2 (0.2)	0.4 (.06)	"	"	"
"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"
4	0	28.5 (3.9)	21.1 (2.7)	13.5 (1.5)	1 (.02)	4	0	10 (0.8)
3	0	20.6 (1.9)	11.2 (3.6)	1.6 (0.2)	1.7 (0.1)	"	"	"
4	0	0.49 (0.03)	12.1 (0.9)	5.6 (0.1)	0.2 (.01)	4	0	0
2	59 (4.1)	0	3.2 (0.5)	0.0	1.2 (.06)	tr	34 (2.1)	0
"	"	"	"	"	"	"	"	"
"	"	"	"	"	"	"	"	"

FIG. 1

FIG. 1

2/10

LABEL #	A	B	C	D	E	F	G	H	I	J	K	L	M
	2-21	2-21-96	3-15	3-20	4-3	4-10	4-17	4-23	5-8	5-16	6-10	7-10	8-14
STUDY II:A Hlg R		1.5	2	3	2.5	2.5	3				4+	4	4
	L	1.6	1	2	3	4	4				4+	DEAD/G+19	
	N		2.5	4	4	4	4				DEAD 6/4		
STUDY II:B Hlg R	1		0.5	2	4	4					DEAD 6/10	DISAPPEAR	
	N		1	3	2.5	3					4+	DISAPPEAR	
STUDY II:C MR1 R	1	2	3	3	3	3		DEAD 4/29					
	L	1.5	1	TRACE	2	2	2		NC	NC	2	4	4
	N	1	2	2	2	NC	DEAD						
	LR	1	1	2	NC	2	2		2	3	NC	3	3
STUDY II:D MR1 R	1	0.5	1	NC	1.6	11/2	1.5	2	NC	2	2	2	2
	N	1	1	1	1	1	NC	2	2	2		2	2

N	O	P	Q	R	S	T	U	V	W	X	Y	Z
6-28	9-11	10-9	10-30	11-6	11-13	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
	4	DEAD 10-2										
4	4	4	NC	4	4	DEAD/11-18						
3	3	NC/DEAD 10-2										
2	4	NC	4	4	4			4	DEAD 11-30			
2	NC	2	TRACE	2	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE

FIG. 2

3/10

		PRE-5-2-96			10-4-96	9/18 5 INJ					11-15-96	10/15 6 INJ
V	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	
AR	tr	13.4(1.3)	4.3(0.5)	"	"	"	"	"	"	"	"	"
AL	tr	0	0	"	"	"	"	"	"	"	"	"
AN	tr	5.4(0.6)	1.3(0.3)	"	"	"	"	"	"	"	"	"
BR	2	2.9(0.1)	0	"	"	"	"	"	"	"	"	"
BL	2	0.8(0.03)	0	"	"	"	"	"	"	"	"	"
BN	2	0	0	4+	ND	ND	13.2 (1.1)	3.3 (0.3)	4+	ND	ND	ND
BLR	2	0	0	"	"	"	"	"	"	"	"	"
CR	2	1.2(0.1)	2.3(0.3)	4	30 (4.6)	ND	0	0	"	"	"	"
CL	1	0.9(0.1)	0	1	0	926(51)	2.6 (0.3)	0	1	0	0.2(0.00)	0
CN	1	0	0	1	68 (3.5)	ND	0	0	1	39 (6.4)	0	0
OR	1	0	0	2	143 (27)	ND	0	0	1	77.5(8.4)	0	0
DL	2	2.9(0.2)	0	1.5	36.6 (6.7)	ND	0	0	1.5	30.4 (6.8)	0.5 (0.00)	0
DN	tr	1.9(0.1)	0		"	"	"	"	"	"	"	"
DLR	1	0	0		"	"	"	"	"	"	"	"

FIG. 3

4/10

	6-8-96	6-17	4-10	4-10	4-26	7-3	7-10	7-17	7-25	7-31	8-14	8-21	8-28	9-4
STUDY V:A Hlg R	TRACE 2		DEAD 6-21											
L NC	TRACE 3			4		4	4	4		4			DEAD 8-24	
N TRACE	TRACE 3			4		4	4	NC		4				
STUDY V:B Hlg R	2				NC	2								
L NC	2				NC	4	4	NC	4+		DEAD 8-13			
N 2/SICK NC	2				NC	2	2	2	2	2	3	3		3
LR TRACE	DEAD 5-12													
STUDY V:C MR1 R	2			2	NC		3	3	4					
L 1	1			2	1	1	1	1	1	1		4		4
N 1	1			1	1	1	1	1	NC	1		1		1
STUDY V:D MR1 R	NC			1	NC	1	2	2	2	2		2		2
L 2	2			2	NC	2	2	1.5	1.5	1.5		NC 1.5		1.5
N TRACE	TRACE NC			1	NC	1	1	1	1	NC		2		2
LR NC	1			2	NC	NC	3	NC	2	3	DEAD 8-14			

	9-11	9-25	10-9	10-23	10-30	11-6	11-13	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
4	DEAD 9-23													
4+	4+													
4														
1														
1	NC													
2	NC													
NC 1:5	1:5													
NC 2	DEAD 9-30													

FIG. 4

5/10

VII	PU	9-30-96 MR1 ug/ml	9/3-7 INJ ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml	PU	11-1-96 MR1 ug/ml	10/1-6 inj. ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml
AN	4	ND	ND	2.4(0.3)	0	0.14(0.03)	"	"	"	"	"	"
BR	4	ND	ND	8.8(0.7)	8.3(0.1)	1.6(0.1)	4	ND	ND			1.2 (0.1)
BL	4	ND	ND	8.3(0.1)	10.1(1.1)	0.6(0.1)	4	ND	ND			0.7 (0.06)
CR	1	35.7 (1.5)	ND	2.7(0.6)	0	0.6(0.1)	1	22.5 (5)	0	1.5 (0)	1.7 (0.2)	1.4 (0.4)
CL	1.5	32(3)	ND	2.0(0.2)	0	0.6(0.1)	1.5	24 (5)	0	0	0.4 (0.07)	0.7 (0.06)
CN	3	24(0.6)	0	2.0(0.1)	1.5(0.1)	0.6(0.06)	3	0	5.3 (0.6)	3.5 (0)	3.7 (0.2)	1.4 (0.4)
CLR	2	36.1(2.8)	0	0	0	0.8(0.06)	1	6.4 (0.6)	0.05(0.002)	1.8 (0)	1 (0.1)	1.4 (0.4)
DR	1	27.6(3.9)	0	2.7(0.6)	0	1.0(0.01)	1	5.9 (0.9)	0.05(0.003)	2.5 (0.9)	2.9 (0.2)	1.3 (0.3)
DL	2	51.3(5.4)	ND	0	0	0.6(0.1)	2	23.6(4)	0	0	0	0.6 (0.1)
DN	1.5	20(4)	0	3.6(1.38)	0	1.1(0.1)	1.5	4.8(0.9)	0	0	0	

	11-20-96 MR1 ug/ml	10/1-6 inj. ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml
PU	"	"	"	"
"	"	"	"	"
4	ND	ND	0	0
1	38.5 (5.7)	0	0	0
tr	47.3 (2.5)	0	98.2 (1.8)	0
(3)	313.6 (52)	0	49.5 (0.2)	0
1	16.2 (0.9)	0	0	0
1	40.6 (7.3)	0 Rev BUN 11/1	0	0
1	71 (6.6)	0	0	0
1.5	85.5 (7.7)	0	0	0

FIG. 5

SUBSTITUTE SHEET (RULE 26)

[illegible]

FIG. 6

7/10

		PRE 10-14-96				11/25/96		
X	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	TOTAL Ig mg/ml	
AR	1	4.2(1.2)	0	2	64.8 (3.3)	24.8 (1)	1.7 (0.08)	
AL	1	2.5(0.3)	0.2(0.0)	2	107.6 (4.2)	11.3 (1)	1.8 (0.1)	
AN	1	5.1(0.7)	4.2(0.5)	4	0	0	0.2 (0.01)	
ALR	tr	0.3(0.1)	0	1	40.9 (1.5)	23 (1.5)	1.8 (0.04)	
BR	2	49.0(3.5)	3.3(0.1)	3	10.8 (1.6)	3.9 (0.4)	5.1 (0.1)	
BL	1	3.8(1.0)	0	3	4.7 (0.2)	3.1 (0.1)	2.1 (0.03)	
BN	tr	5.1(0.02)	0	1	26.8 (3.8)	15.9 (2.6)	7.4 (0.8)	
BLR	1	3.0(0.3)	0	1	22.1 (3.2)	23.1 (0.4)	5.9 (0.6)	
CR	1	17.8(2.8)	6.7(0.8)	1	124 (0)	0	2.7 (0.04)	
CL	1	0	18.9(2.2)	1	140 (23)	68.7 (5.6)	2.8 (0.1)	
CN	1	1.03(0.3)	0.6(0.10)	1	0	0	1.3 (0.1)	
CLR	tr	22.6(2.08)	7.7(1.06)	0.5	18.6 (1.6)	6.1 (0.3)	1.5 (0.1)	
DR	3	0	0	4	70.3 (7.5)	0	0.9 (0.03)	
DL	1	4.3(0.6)	3.6(0.6)	1	8.4 (0.1)	0	2.2 (0.2)	
DN	tr	5.1(1.1)	8.6(0.1)	0.5	42.5 (4.6)	0		
DLR	tr	0	0	0.5	0	0		

FIG. 7

	9-16	9-25	10-2	10-9	10-14	10-23	10-30	11-6	11-13	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
STUDY X:A Ha4/8 R					1	2	2	2	2	2	NC	2	3	3	3	4
L					1	1	1	1	1	1	2	NC	2	3	3	3
N					1	2.5	2.5	3	4+	4+	4+	4+	4+	DEAD12-18		
LR					TRACE	TRACE	1	1	1	1	1	4	NC	4	4	4
STUDY X:A Ha4/8 R					2	2	NC	3	NC	3	NC	3	NC	3	3	4
L					1	1	1	2	NC	2	3	3	3	4	4	4
N					TRACE	1	1	1	1	1	1	2	1	3	4	NC
LR					1	1	1	1	1	1	1	1	1	1	1	1
STUDY X:C MR1 R					1	1	1	1	1	1	1	1	1	NC	4	NC
L					1	1	1	1	NC	1	1	NC	1	1	2	2
N					1	1	1	1	1	1	1	1	1	1	1	1
LR					TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	1
STUDY X:D MR1 R					3	3	3	4	4	4	4	4	4	4	1	4
L					1	1	NC	1	1	1	1	NC	1	2	1	3
N					TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	1	1	1	1	NC
LR					TRACE	TRACE	TRACE	TRACE	NC	TRACE	TRACE	TRACE	TRACE	TRACE	NC	NC

FIG. 8

9/10

		10-2-96	10/1 -8 INJ			11-1-96	10/1 -8 INJ		
VI	PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml	ANTI-DSDNA ug/ml	PU	MR1 ug/ml	ANTI-MR1 ug/ml	ANTI-SSDNA ug/ml
DN	4	8.1 (1.4)	0.64 (0.8)	17.9(1.1)	12.9(0.4)	"	"	"	"
ER	1	153 (7.8)	ND	0	0	1	27 (6)	0	3.2 (1.3)
EL	3	46.7 (4.6)	0.35 (0.09)	10.8(0.9)	7.4(0.3)	3	0	4.9(0.2)	0
EN	3	25 (3.5)	0	5.6(0.6)	3.1(0.6)	"	"	"	"

	11-20-96	11/5 -9 INJ
PU	MR1 ug/ml	ANTI-MR1 ug/ml
"	"	"
1	90 (9.8)	0
3	151.7 (4.6)	0.5 (.04) REV BUN 11/1
"	"	"

FIG. 9

10/10

	6-24	7-10	7-17	7-25	7-31	8-14	8-21	8-28	9-4	9-11	9-25	10-2
STUDY VI:A Hlg R	3.5	3	3	4		DEAD8-10						
N		3	NC	3	4	4				4	DEAD9-15	
STUDY VI:B Hlg N	4	4	4			4				4+	4+	DEAD9-30
STUDY VI:C Hlg N	1.5	3	3	4+		4				DEAD9-11		
STUDY VI:D MR1 N	4	4	4			4		4		4	4	4
STUDY VI:E MR1 R	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	TRACE	NC	1
L	2.5	2.5	2.5	2.5	NC	3	3	3	3	3	3	NC
N	2.5	2.5	NC	2.5	3	3	2.5	3	3	3	NC	3

10-9	10-23	10-30	11-6	11-15	11-20	11-27	12-4	12-11	12-18	12-26	1-1-97
DEAD10-20											
NC	1	1	1	1	1	1	1	1	1	1	1
3	3	3	3	3	3	3	NC	3	DEAD12-18		
3	DEAD10-21										

FIG. 10

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 98/00573

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A61K39/395		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 23071 A (BRISTOL-MYERS SQUIBB COMPANY) 1 August 1996 see page 27, line 22 - line 33 see example 10 see claims	1-24
X	WO 93 09812 A (TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK) 27 May 1993 see claims	1-24

	-/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 18 May 1998		Date of mailing of the international search report 24.06.1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Nooij, F

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/00573

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	F. DURIE ET AL.: "Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40." SCIENCE, vol. 261, no. 5126, 3 September 1993, WASHINGTON, DC, USA, pages 1328-1330, XP002064747 cited in the application see abstract see page 1328, right-hand column, line 57 - left-hand column, line 7 ---	1-17
A	WO 95 06480 A (TRUSTEES OF DARTMOUTH COLLEGE) 9 March 1995 see claims ---	1-5
A	K. GERRITSE ET AL.: "CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 93, no. 6, 19 March 1996, WASHINGTON, DC, USA, pages 2499-2504, XP002064748 see the whole document ---	6-17
A	G. EARLY ET AL.: "Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice." THE JOURNAL OF IMMUNOLOGY, vol. 157, no. 7, 1 October 1996, BALTIMORE, MD, USA, pages 3159-3164, XP002064749 see the whole document -----	6-17

INTERNATIONAL SEARCH REPORT

Int. l. application No.
PCT/US 98/00573

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern Application No

PCT/US 98/00573

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9623071	A	01-08-1996	AU 4966996	A 14-08-1996
			CA 2210419	A 01-08-1996
			CZ 9702339	A 12-11-1997
			EP 0807175	A 19-11-1997
			FI 973120	A 25-07-1997
			NO 973447	A 26-09-1997

WO 9309812	A	27-05-1993	US 5474771	A 12-12-1995
			AU 675922	B 27-02-1997
			AU 3141993	A 15-06-1993
			CA 2123224	A 27-05-1993
			EP 0614374	A 14-09-1994
			JP 7505761	T 29-06-1995

WO 9506480	A	09-03-1995	AU 7643094	A 22-03-1995
			CN 1137758	A 11-12-1996
			EP 0742721	A 20-11-1996
			FI 960979	A 30-04-1996
			HU 74251	A 28-11-1996
			JP 9502184	T 04-03-1997
			NO 960863	A 30-04-1996
			ZA 9406765	A 15-02-1996
			AU 3518397	A 30-10-1997
			AU 7642994	A 22-03-1995
			AU 678532	B 29-05-1997
			AU 7644594	A 22-03-1995
			CN 1134113	A 23-10-1996
			EP 0721469	A 17-07-1996
			EP 0721346	A 17-07-1996
			FI 960978	A 29-04-1996
			FI 960980	A 30-04-1996
			HU 74246	A 28-11-1996
			HU 74250	A 28-11-1996
			JP 9502096	T 04-03-1997
			JP 9502186	T 04-03-1997
			NO 960861	A 30-04-1996
			NO 960862	A 30-04-1996
			NZ 273207	A 22-09-1997
			WO 9506666	A 09-03-1995
			WO 9506481	A 09-03-1995

Information on patent family members

PCT/US 98/00573

Form PCT/ISA/210 (patent family annex) (July 1992)